Super Bowl ads are not cheap. That is what brands pay.
Brands like Duncan ‘, Uber Eight and Cores Light are willing to pay millions of dollars for super -bowl ads
Drug industry allies have called for a super -bowl ad on the drug to lose weight from the television company Hames and Assis, and claimed that the safety risks of these drugs are not properly disclosed. –
The ad has criticized the $ 160 billion weight loss industry, and shows that a person selects the company’s weight loss offers by a smart phone. Although this advertisement does not indicate drugs, Hamas and Ascens offer a complex version of weight loss drug smugglotide, which was developed by Novo Nordesk and is usually sold under the names of Vigo and Ozampic –
A group of more than 40 community and pharmacy groups, partnerships for safe medicine, asked the Food and Drug Administration to “take action” and “save Americans from misleading marketing in health products.” The group also requested Fox, a broadcasting game to withdraw “deeply disturbing ads” before it was broadcast on Sunday.
Pharmaceutical research and US manufacturers, a business group representing drug dealers, said the ad violates a federal rule that does not need to be wrong or misleading drug ads. There is The ad was posted on YouTube ahead of Sunday’s title game between Philadelphia Eagles and Kansas City Chiefs.
Friday, senses. Dick Durban, D Eli, and Roger Marshall, R Kan, said in one Line Advertisement for the FDA is at risk of misleading patients as it leaves information about drug safety and side effects.
Hims & Hers, who marketing weight loss and other drugs, said the company is not a drug manufacturer and does not need to follow the same advertising standards. San Francisco -based company connects consumers with licensed health providers who are diagnosed online and write medicines if appropriate. The company said it follows advertising requirements for television platforms.
In a statement, Hams & Asus said the drug industry is trying to cancel an advertisement that “directly phoned that they are part of a system that fails to prioritize Americans’ health This is another example of this system.
Why are groups worried about advertising?
In a letter sent to the FDA on Wednesday, the contribution of safe medicine stated that the 1 -minute ad is “completely misleading” because it does not reveal that compound drugs are not approved by FDA And there are a threat to patients. The organization also challenged the language that the drug was “developed in the United States.” The letter states that HIMS & HERS Markets “Knock -off version of Simglotide – a drug that Novo Nordesk had formed after decades of research and billions of investments.”
According to Shabbir Amber Safdar, executive director of the group, neither the FDA nor the Fox responded to the group’s territories until Thursday afternoon.
In a statement on Thursday, the PHRMA said the ad did not cite the potential risks and side effects of the compound GLP-1 drugs. The PHRMA said the ad was shown in the ad, describing drug images as “life -changing weight loss medicines” and “Dr. Trusted”.
The audience is expected to join the Sunday match -up, which is firmly competing with the 2023 super bowl. Last year, the game between Chiefs and San Francisco 49ers attracted more than 123 million viewers, watching at least one part of the game more than 202 million.
Drug companies in difficulties with compound pharmacies
Amid the Super Bowl advertising dispute is a major battle between drug companies that markets profitable weight loss drugs and firms that sell less expensive versions produced by compound pharmacies.
The FDA allows compound pharmacies to sell copies of drugs when the supply of medicines decreases. But when drug shortages are resolved, compounding pharmacies face severe sanctions.
Hems & Assis Markets developed a nao -nordsesk’s semoglatide version, this is a medicine Stays in a shortageThe FDA said. Nova Nordsesk sells drugs under the brand names of Weegovy’s brand names for obesity and heart disease and ozampic treatment to treat type 2 diabetes.
In December, the FDA announced that Eli Lily’s weight loss and diabetes drug tearzipitide, which was sold under brand names, sold under Moujaro and Zip Bound, was no longer low. This means that pharmacies are up to time February 18 “Compounding, distributing or dispensing” Terizapatide closing. Suppliers who manufacture drugs and sell to others until March 19 To eliminate the partition.
Compounding pharmacies are regularly made by the Pharmacy State Board and are usually obtained from the FDA registered factories. However, the federal agency does not confirm the safety or effect of compounding pharmacies.
